PepGen Therapeutics is creating the next generation of oligonucleotide therapies to transform treatments of neuromuscular diseases. Oligonucleotides delivered into cells can modulate RNA expression to treat disease. PepGen is using their proprietary Enhanced Delivery Oligonucleotide (EDO) platform to identify cell-penetrating peptide conjugates that improve the activity and tolerability of oligonucleotide cargo therapeutics. PepGen’s proprietary EDO peptides are engineered for optimal tissue and cell penetration and have been shown to transport oligonucleotides into many target tissues including skeletal and cardiac muscle. PepGen is generating a pipeline of oligonucleotide therapies that target the root cause of serious neuromuscular diseases.